Research News
Share:
BySpondylitis Association of America

FDA Approves JAK Inhibitor Upadacitinib (Rinvoq) for Psoriatic Arthritis

A new medication has been approved by the U.S. FDA for the…

Read more
BySpondylitis Association of America

A New Biologic Medication, Bimekizumab, Shows Promise for Axial Spondyloarthritis

Bimekizumab is a first-of-its-kind dual IL-17 inhibitor that targets both IL-17A and…

Read more
BySpondylitis Association of America

New Treatment Approved for Ankylosing Spondylitis: FDA OKs First JAK…

The U.S. FDA has approved a new medication to treat…

Read more
BySpondylitis Association of America

Introducing SAA’s Primary Care and Chiropractic Initiative: Accredited Continuing Education…

SAA is rolling out two accredited continuing education programs to…

Read more
BySpondylitis Association of America

Researchers Identify Potential New Treatment Target for Axial Spondyloarthritis

Researchers at the University of Toronto in Ontario, Canada have uncovered a…

Read more
BySpondylitis Association of America

First Interchangeable Biosimilar Approved for Humira

The FDA has approved the first interchangeable biosimilar for adalimumab (Humira), a TNF inhibitor commonly taken for spondyloarthritis…

Read more
1 7 8 9 10 11 24
SAA desktop logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.